Ashton, NJ;
Suárez-Calvet, M;
Heslegrave, A;
Hye, A;
Razquin, C;
Pastor, P;
Sanchez-Valle, R;
... Zetterberg, H; + view all
(2019)
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
Alzheimer's Research & Therapy
, 11
, Article 94. 10.1186/s13195-019-0545-5.
Preview |
Text
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.pdf - Published Version Download (703kB) | Preview |
Abstract
Background: Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. / Methods: In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers. / Results: Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. / Conclusion: Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.
| Type: | Article |
|---|---|
| Title: | Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s13195-019-0545-5 |
| Publisher version: | https://doi.org/10.1186/s13195-019-0545-5 |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Keywords: | Alzheimer’s disease, sTREM2, Blood, Biomarkers, Neurofilament light chain |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10089786 |
Archive Staff Only
 |
View Item |
